Genetic variants may explain why some individuals respond poorly to GLP-1 receptor agonist medications, such as Ozempic. These drugs are used to treat Type 2 diabetes. Approximately ten percent of the population carries these genetic variants.
Individuals with these variants appear to produce higher levels of the hormone GLP-1 (glucagon-like peptide-1). However, the hormone does not function as effectively in their bodies. This suggests a form of GLP-1 resistance.
Researchers found that carriers of these variants were significantly less likely to achieve healthy blood sugar targets. This was observed in several clinical trials involving GLP-1 medications. The study focused on blood sugar control. It did not reach firm conclusions about weight loss effects.
Scientists from Stanford Medicine and international collaborators conducted the research. The study involved human and mouse experiments. It also analyzed data from diabetes medication clinical trials. The findings were published in *Genome Medicine*.
Related stories
New Alzheimer's Drug Target Identified, Experimental Compound Shows Promise
Scientists at ETH Zurich identified a new Alzheimer's trigger and developed an experimental compound that slowed nerve cell loss and extended lifespan in mice.
Brain Chemical Acetylcholine Linked to Breaking Bad Habits
Scientists have identified acetylcholine as a key brain chemical that helps individuals break bad habits and adapt to new situations, with implications for treating addiction and neurological disorders.
Texas screwworm outbreak leads to Canada cattle import ban.
A second case of screwworm infection has been confirmed in Texas cattle, intensifying concerns among agricultural authorities. This significant development has ...